Epithelial ovarian carcinoma: ESMO clinical recommendations for diagnosis, treatment and follow-up

Annals of Oncology

Volumn 19, Issue SUPPL. 2, 2008, Pages

  Aebi, S ^a,c   Castiglione, M ^b,c  

^a UNIVERSITY OF BERN   (Switzerland)

^b ESMO Head Office ^*

^c ESMO HEAD OFFICE   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CA 125 ANTIGEN; CARBOPLATIN; PACLITAXEL;

ABDOMINAL HYSTERECTOMY; ADVANCED CANCER; ANTIGEN DETECTION; ARTICLE; CANCER ADJUVANT THERAPY; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER MORTALITY; CANCER STAGING; CANCER SURVIVAL; CANCER THERAPY; CYTOREDUCTIVE SURGERY; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; MULTIPLE CYCLE TREATMENT; OVARY CARCINOMA; PRACTICE GUIDELINE; PRIORITY JOURNAL; RECURRENT CANCER; RISK ASSESSMENT; SALPINGOOOPHORECTOMY; TREATMENT PLANNING; TREATMENT RESPONSE; CARCINOMA; INCIDENCE; OVARY TUMOR; PATHOLOGY;

CARCINOMA; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; NEOPLASM STAGING; OVARIAN NEOPLASMS;

EID: 45149101019     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdn073     Document Type: Article

References (21)

1. Armstrong DK, Bundy B, Wenzel L et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 2006; 354: 34-43.
2. Bell J, Brady MF, Young RC et al. Randomized phase III trial of three versus six cycles of adjuvant carboplatin and paclitaxel in early stage epithelial ovarian carcinoma: A Gynecologic Oncology Group study. Gynecol Oncol 2006; 102: 432-439,
3. Bristow RE, Chi DS. Platinum-based neoadjuvant chemotherapy and interval surgical cytoreduction for advanced ovarian cancer: A meta-analysis. Gynecol Oncol 2006; 103: 1070-1076.
4. Bristow RE, Eisenhauer EL, Santillan A, Chi DS. Delaying the primary surgical effort for advanced ovarian cancer: A systematic review of neoadjuvant chemotherapy and interval cytoreduction. Gynecol Oncol 2007; 104: 480-490.
5. Bristow RE, Tomacruz RS, Armstrong DK et al. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: A meta-analysis. J Clin Onool 2002; 20: 1248-1259.
6. du Bois A, Luck H-J, Meier W et al. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst 2003; 95: 1320-1329.
7. Fader AN, Rose PG. Role of surgery in ovarian carcinoma. J Clin Oncol 2007; 25: 2873-2883.
8. Gordon AN, Tonda M, Sun S, Rackoff W. Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithetial ovarian cancer. Gynecol Oncol 2004; 95: 1-8.
9. ICON Collaborators. Paclitaxel plus carboplatin vensus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: The ICON3 randomised trial. Lancet 2002; 360: 505-515.
10. Markman M, Liu PY, Rothenberg ML et al. Pretreatment CA-125 and risk of relapse in advanced ovarian cancer. J Clin Oncol 2006; 24: 1454-1458.
11. Markman M, Liu PY, Wilczynski S et al. Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: A Southwest Oncology Group and Gynecologic Oncology Group trial. J Clin Oncol 2003; 21: 2460-2465.
12. McGuire WP, Hoskins WJ, Brady ME et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996; 334: 1-6.
13. Ozols RF, Bundy BN, Greer BE et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxell in patents with optimally resected stage III ovarian cancer: A Gynecologic Oncology Group study. J Clin Oncol 2003; 21: 3194-3200.
14. Pfisterer J, Plante M, Vergote I et al. Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: An intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. J Clin Oncol 2006; 24: 4699-4707.
15. Piccart MJ, Bertelsen K, James K et al. Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: Three-year results. J Natl Cancer Inst 2000; 92: 699-708.
16. Rose PG, Nerenstone S, Brady MF et al. Secondary surgical cytoreduction for advanced ovarian carcinoma. N Engl J Med 2004; 351: 2489-2497.
17. Rustin GJ, Bast RC Jr, Kelloff GJ et al. Use of CA-125 in clinical trial evaluation of new therapeutic drugs for ovarian cancer. Clin Cancer Res 2004; 10: 3919-3926.
18. Rustin GJS, Nelstrop AE PM et al. Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125. J Clin Oncol 1996; 14: 1545-1551.
19. Trimbos JB, Parmar M, Vergote I et al. International collaborative ovarian neoplasm trial 1 and adjuvant chemotherapy in ovarian neoplasm trial: Two parallel randomized phase III trials of adjuvant chemotherapy in patients with early-stage ovarian carcinoma. J Natl Cancer Inst 2003; 95: 105-112.
20. van der Burg ME, van Lent M, Buyse M et al. The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. Gynecological Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer. N Engl J Med 1995; 332: 629-634.
21. Vergote I, De Brabanter J, Fyles A et al. Prognostic importance of degree of differentiation and cyst rupture in stage I invasive epithelial ovarian carcinoma. Lancet 2001; 357: 176-182.